Teva Pharmaceutical Industries Limited TEVA
41.91 USD +1.21 (+2.97%)
At closeNov 3, 2026, 4:59 PM EST
41.85 -0.06 -0.15%
After hours · Nov 3, 4:59 PM ET
41.54 Day range 43.34
20.11 52-week range 43.34
- YTD
- +34.28%
- 1 year
- +104.24%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 47.92 +14.3% upside
Now 41.91
- Target (low)
- 42.00
- Target (mean)
- 47.92
- Target (high)
- 55.00
Ratings (0m) 14 13 buy · 1 hold · 0 sell
- Strong buy4
- Buy9
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 14
- 1 month ago 13
- 2 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.75562 | 0.68 – 0.97 | 0.00 | 0.0% | 4.25B | -9.8% | 12 |
| Next quarter | 0.6285 | 0.56 – 0.70 | 0.00 | 0.0% | 4.08B | +2.4% | 8 |
| Current year | 2.09 | 1.91 – 2.94 | 0.00 | 0.0% | 16.66B | -3.5% | 15 |
| Next year | 3.08 | 2.86 – 3.35 | 2.09 | +47.6% | 17.25B | +3.6% | 15 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | HC Wainwright & Co. | Initiated | — | Buy |
| Oct 15, 2026 | Barclays | Maintained | Overweight | Overweight |
| Oct 12, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 1, 2026 | TD Cowen | Initiated | — | Buy |
| Sep 23, 2026 | Oppenheimer | Initiated | — | Outperform |
| Sep 9, 2026 | Leerink Partners | Initiated | — | Outperform |
| Sep 4, 2026 | UBS | Maintained | Buy | Buy |
| Aug 12, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jul 28, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| May 6, 2026 | Barclays | Maintained | Overweight | Overweight |
| Apr 30, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Apr 30, 2026 | UBS | Maintained | Buy | Buy |
| Apr 30, 2026 | Piper Sandler | Reiterated | Overweight | Overweight |
| Apr 30, 2026 | Truist Securities | Maintained | Buy | Buy |
| Apr 9, 2026 | B of A Securities | Maintained | Buy | Buy |
| Mar 4, 2026 | Piper Sandler | Reiterated | Overweight | Overweight |
| Feb 18, 2026 | Truist Securities | Maintained | Buy | Buy |
| Feb 9, 2026 | Goldman Sachs | Maintained | Buy | Buy |
| Jan 30, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jan 29, 2026 | Scotiabank | Maintained | Sector Outperform | Sector Outperform |
| Jan 29, 2026 | Truist Securities | Maintained | Buy | Buy |
| Jan 6, 2026 | Jefferies | Maintained | Buy | Buy |
| Dec 22, 2025 | Piper Sandler | Maintained | Overweight | Overweight |
| Dec 19, 2025 | Goldman Sachs | Maintained | Buy | Buy |
| Dec 16, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Dec 9, 2025 | B of A Securities | Maintained | Buy | Buy |
| Dec 9, 2025 | Barclays | Initiated | — | Overweight |
| Dec 8, 2025 | Goldman Sachs | Maintained | Buy | Buy |
| Dec 5, 2025 | Scotiabank | Initiated | — | Sector Outperform |
| Nov 6, 2025 | JP Morgan | Maintained | Overweight | Overweight |
